GlyCardial Diagnostics’ technology is based on the quantification of specific protein modifications as a novel and disruptive approach to detect cardiac ischemia
GlyCardial Diagnostics’ technology is based on the quantification of specific protein modifications as a novel and disruptive approach to detect cardiac ischemia
The standard techniques used for the measurement of biomarkers are usually directed to determine total protein levels.
The importance of proteins in a disease is not only through their quantity but also through their structure and/or post-translational modifications.
Monitoring changes in serum glycoproteins may be a more specific and sensitive approach than the analysis of total protein levels for the detection of acute ischemic events.
The development of our novel assay would represent:
due to the current lack of early biomarkers for the detection of ischemia for the diagnosis and prognosis of ischemic events
as we will obtain a sensitive and reproducible method to allow the rapid quantification of the glycosylated forms of a specific glycoprotein